Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

Reneo Pharmaceuticals, Inc. (RPHM)

7.39   -0.26 (-3.4%) 09-27 11:26
Open: 7.61 Pre. Close: 7.65
High: 7.93 Low: 7.32
Volume: 62,190 Market Cap: 250(M)

Technical analysis

as of: 2023-09-27 10:49:20 AM
Short-term rate:       
Stoxline posted a NEUTRAL today, same as yesterday. Current trend continues, but could change at anytime. It is not a good time to buy or sell.
Mid-term rate:       
Target: Six months: 9.92     One year: 11.59
Support: Support1: 6.81    Support2: 5.78
Resistance: Resistance1: 8.5    Resistance2: 9.92
Pivot: 7.28
Moving Average: MA(5): 7.56     MA(20): 7.06
MA(100): 7.22     MA(250): 5.24
MACD: MACD(12,26): 0.2     Signal(9): 0.2
Stochastic oscillator: %K(14,3): 69.1     %D(3): 75.4
RSI: RSI(14): 60.3
52-week: High: 11.29  Low: 1.78
Average Vol(K): 3-Month: 137 (K)  10-Days: 140 (K)

Price, moving averages and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.
[ RPHM ] has closed below upper band by 15.3%. Bollinger Bands are 46.2% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 3 bars. This is a sign that the market may be about to initiate a new trend.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 8.51 - 8.56 8.56 - 8.6
Low: 7.5 - 7.55 7.55 - 7.59
Close: 7.58 - 7.66 7.66 - 7.73

Company Description

Reneo Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the development of therapies for patients with rare genetic mitochondrial diseases. It develops REN001, a selective peroxisome proliferator-activated receptor delta agonist, which is in Phase IIb clinical trial in patients with primary mitochondrial myopathies, as well as in Phase 1b clinical trial in patients with long-chain fatty acid oxidation disorders and glycogen storage disease type V. Reneo Pharmaceuticals, Inc. was incorporated in 2014 and is headquartered in San Diego, California.

Headline News

Fri, 22 Sep 2023
Prelude Capital Management LLC Invests $89000 in Reneo ... - MarketBeat

Tue, 29 Aug 2023
Reneo Pharmaceuticals to Participate in Upcoming Investor ... - GlobeNewswire

Thu, 10 Aug 2023
Reneo Pharmaceuticals, Inc.'s (NASDAQ:RPHM) stock price dropped 10% last week; private equity firms would not be happy - Yahoo Finance

Mon, 31 Jul 2023
Should Biotechnology Stock Reneo Pharmaceuticals Inc (RPHM) Be in Your Portfolio Monday? - InvestorsObserver

Mon, 26 Jun 2023
Reneo Pharmaceuticals Added to Russell 2000® and Russell 3000® Indices - Yahoo Finance

Mon, 05 Jun 2023
Is Reneo Pharmaceuticals Inc (RPHM) Stock a Good Value Monday? - InvestorsObserver

Financial Analysis

Price to Book Value: Outperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Underperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Underperform
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Underperform
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Neutral
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. 34 (M)
Shares Float 15 (M)
% Held by Insiders 2 (%)
% Held by Institutions 58.9 (%)
Shares Short 2,030 (K)
Shares Short P.Month 1,470 (K)

Stock Financials

EPS -2.25
EPS Est Next Qtl 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 3.92
Profit Margin (%) 0
Operating Margin (%) 0
Return on Assets (ttm) -29.2
Return on Equity (ttm) -47.8
Qtrly Rev. Growth 0
Gross Profit (p.s.) 0
Sales Per Share 0
EBITDA (p.s.) -1.94
Qtrly Earnings Growth 0
Operating Cash Flow -52 (M)
Levered Free Cash Flow -30 (M)

Stock Valuations

PE Ratio -3.42
PEG Ratio 0
Price to Book value 1.95
Price to Sales 0
Price to Cash Flow -5.04

Stock Dividends

Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
Your Ad Here
StockChart iOS
StoxlineLite iOS
StoxlineLite iOS
OptionCalc iOS
StockChart Android
StoxlineLite Android
StoxlinePro Android
OptionCalc Android
(c) 2006-2022 | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the web site, a user agrees not to redistribute the information found therein.